Ann Oncol: Phase II clinical study ROAR update: the efficacy of Dabrafenib (dabrafenib) combined with trametinib (trametinib) in the treatment of BRAF V600E mutant anaplastic thyroid cancer

According to the results of the anaplastic thyroid cancer (ATC) cohort study of the phase II clinical study ROAR, many countries have approved Dabrafenib (dabrafenib) in combination with trametinib (trametinib) for the treatment of BRAF V600E mutant anaplastic thyroid cancer (ATC)
.

Recently, the journal Annals of Oncology updated the results of the 4-year follow-up time of 36 ATC patients in the ROAR study

According to the results of the anaplastic thyroid cancer (ATC) cohort study of the phase II clinical study ROAR, many countries have approved Dabrafenib (dabrafenib) in combination with trametinib (trametinib) for the treatment of BRAF V600E mutant anaplastic thyroid cancer (ATC)

ROAR is an open-label, nonrandomized, phase II basket study evaluating dabrafenib plus trametinib in rare cancers with BRAF V600E mutations
.

The primary endpoint was overall response rate (ORR)

ROAR is an open-label, nonrandomized, phase II basket study evaluating dabrafenib plus trametinib in rare cancers with BRAF V600E mutations

Of the 36 patients included, 20 (56%) were female, with a median age of 71.

The investigator-assessed ORR was 56% (95% CI, 38.

The median progression-free survival (PFS) by investigator assessment and independent committee assessment was 6.
7 months (95% CI, 4.
7-13.
8 months) and 5.
5 months (95% CI, 3.
7-12.
9 months), respectively
.

Investigator-assessed 12- and 24-month PFS rates were 43.

The median progression-free survival (PFS) by investigator assessment and independent committee assessment was 6.

All patients experienced ≥1 AE, including 27 patients with dabrafenib + trametinib-related AEs (75%)
.

The most common all-cause AEs were pyrexia (47%); anemia (36%); decreased appetite, fatigue, and nausea (both 33%)

All patients experienced ≥1 AE, including 27 patients with dabrafenib + trametinib-related AEs (75%)

In conclusion, the updated data of the ROAR study further confirmed the efficacy of dabrafenib + trametinib in the treatment of BRAF V600E-mutated anaplastic thyroid cancer (ATC)
.

In conclusion, the updated data of the ROAR study further confirmed the efficacy of dabrafenib + trametinib in the treatment of BRAF V600E-mutated anaplastic thyroid cancer (ATC)
.

The updated data from the ROAR study further confirmed the efficacy of dabrafenib + trametinib in the treatment of BRAF V600E-mutated anaplastic thyroid cancer (ATC)

Original source:

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Palanichamy I, Burgess P, Romero Salas T, Keam B.
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Ann Oncol.
2022 Jan 10:S0923-7534(22)00005-9.
doi: 10.
1016/j.
annonc.
2021.
12.
014.
Epub ahead of print .
PMID: 35026411.

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Palanichamy I, Burgess P, Romero Salas T, Keam B.
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Ann Oncol.
2022 Jan 10:S0923-7534(22)00005-9.
doi: 10.
1016/j.
annonc.
2021.
12.
014.
Epub ahead of print .
PMID: 35026411.
Leave a message here